Key result
In an 8-year Markov model, valsartan increased mean quality-adjusted survival compared to amlodipine (77 vs 70 months; P<0.01) and lowered medical costs ($92,058 vs $124,470; P<0.01).
Why the study?
Does valsartan improve quality-adjusted survival and reduce medical costs compared to amlodipine in patients with type 2 diabetes and microalbuminuria?
Does valsartan improve quality-adjusted survival and reduce medical costs compared to amlodipine in patients with type 2 diabetes and microalbuminuria?
Absolute Event Rate: 77% vs 70%
p-value: p=<0.01
Markov modeling projects that valsartan provides better quality-adjusted survival and lower medical costs over 8 years compared to amlodipine in patients with type 2 diabetes and microalbuminuria.
No takes yet. Share an insight, caveat, or question.
May support valsartan preference for projected QALY gains and cost savings in diabetic microalbuminuria; extends MARVAL but leaves prospective confirmation open.
Smith et al. (2004) studied Type 2 diabetes and microalbuminuria. Valsartan vs. Amlodipine was evaluated on Quality-adjusted survival (months) (p=<0.01). In an 8-year Markov model, valsartan increased mean quality-adjusted survival compared to amlodipine (77 vs 70 months; P<0.01) and lowered medical costs ($92,058 vs $124,470; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: